
Alexandria Real Estate Equities-backed exosome therapeutics developer Codiak BioSciences is eyeing up to $86.3m in a forthcoming IPO.
The immuno-oncology therapy developer received funding from investors including Alexandria Real Estate Equities and strategic collaborator Celgene.
The Eli Lilly and Mitsui-backed drug developer has received $11m in a round led by Cell Innovation Partners, taking its overall funding to more than $83m.
Taikang Life Insurance backed a $14.8m round for the online medical data platform, which already counts Fosun, DXY and Meituan Dianping as shareholders.
908 Devices plans to add a life science device to its chemical detection product range, having landed $17.5m in a Schlumberger and Saudi Aramco-backed round.
Telus Ventures is set to exit healthcare data management software producer Get Real Health in an $11m purchase by CPSI, six years after it invested.
MRCF has reached the first close of a CSL-backed fifth fund to make early-stage investments in medical technologies in Australia and New Zealand.
Digital China Health Technologies chipped into the third tranche of a round featuring fellow corporates BGI Genomics and Healthlink that now tops $30m.
Alphabet, WuXi AppTec, Celgene, Roche and Novartis are in line to exit precision oncology therapy developer Ideaya Biosciences, which has filed to go public.
Astellas, Novartis and GlaxoSmithKline are in line for exits as oncology drug developer Bicycle Therapeutics prepares to float, having filed to raise $86m in its IPO.